Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:CASC's Cash-to-Debt is ranked higher than
100% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. NAS:CASC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CASC' s Cash-to-Debt Range Over the Past 10 Years
Min: 13.29  Med: 156.02 Max: No Debt
Current: No Debt
Interest Coverage No Debt
NAS:CASC's Interest Coverage is ranked higher than
100% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:CASC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:CASC' s Interest Coverage Range Over the Past 10 Years
Min: 1060.29  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 2.15
Beneish M-Score: -3.80
WACC vs ROIC
25.81%
-313.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE % -73.45
NAS:CASC's ROE % is ranked lower than
69% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. NAS:CASC: -73.45 )
Ranked among companies with meaningful ROE % only.
NAS:CASC' s ROE % Range Over the Past 10 Years
Min: -163.15  Med: -65.96 Max: 45.34
Current: -73.45
-163.15
45.34
ROA % -62.77
NAS:CASC's ROA % is ranked lower than
72% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:CASC: -62.77 )
Ranked among companies with meaningful ROA % only.
NAS:CASC' s ROA % Range Over the Past 10 Years
Min: -80.5  Med: -50.43 Max: 24.26
Current: -62.77
-80.5
24.26
ROC (Joel Greenblatt) % -4105.56
NAS:CASC's ROC (Joel Greenblatt) % is ranked lower than
77% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. NAS:CASC: -4105.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CASC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4105.56  Med: -2109.3 Max: 661.83
Current: -4105.56
-4105.56
661.83
3-Year EBITDA Growth Rate -5.20
NAS:CASC's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. NAS:CASC: -5.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CASC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -60.2  Med: -8.3 Max: 91.8
Current: -5.2
-60.2
91.8
3-Year EPS without NRI Growth Rate -5.60
NAS:CASC's 3-Year EPS without NRI Growth Rate is ranked lower than
54% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:CASC: -5.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CASC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57  Med: -11.3 Max: 28.8
Current: -5.6
-57
28.8
GuruFocus has detected 1 Warning Sign with Cascadian Therapeutics Inc $NAS:CASC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CASC's 10-Y Financials

Financials (Next Earnings Date: 2017-06-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CASC Guru Trades in

Q2 2016

CASC Guru Trades in Q2 2016

First Eagle Investment 400,000 sh (New)
Seth Klarman 25,000,000 sh (New)
Paul Tudor Jones 48,760 sh (New)
» More
Q3 2016

CASC Guru Trades in Q3 2016

First Eagle Investment 400,000 sh (unchged)
Paul Tudor Jones 48,760 sh (unchged)
Seth Klarman 25,000,000 sh (unchged)
» More
Q4 2016

CASC Guru Trades in Q4 2016

Seth Klarman 4,166,666 sh (unchged)
Paul Tudor Jones Sold Out
First Eagle Investment 24,999 sh (-62.50%)
» More
» Details

Insider Trades

Latest Guru Trades with CASC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 8731
Compare:OTCPK:OXBDF, NAS:ENZY, OTCPK:ELVAF, NAS:MNOV, NAS:TRVN, NAS:NVLN, NAS:FATE, NAS:CYAD, NAS:VTVT, NAS:SRNE, OTCPK:SPRWF, NAS:ABEO, NAS:PPHM, NAS:CDXS, NAS:STML, OTCPK:SPHRY, NAS:PETX, NAS:CEMP, NAS:KURA, AMEX:MTNB » details
Traded in other countries:3O61.Germany,
Oncothyreon Inc is a clinical-stage biopharmaceutical company. It develops and commercialize synthetic vaccines & small molecules that treat the lives & outcomes of cancer patients.

Oncothyreon Inc was incorporated on September 7, 2007. The Company is a clinical-stage biopharmaceutical company that develops therapeutic products for the treatment of cancer. Its cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company's cancer vaccine product candidate, tecemotide, formerly known as L-BLP25 or Stimuvax, is being evaluated for the treatment of non-small cell lung cancer, or NSCLC. It has granted license to Merck KGaA of Darmstadt, Germany, or Merck KGaA, for the development, manufacture and commercialization of tecemotide. The Company is also conducting Phase 1 trial for ONT-10, a cancer vaccine. The Company's pipeline of products includes immunotherapies and small molecules. The Company currently outsources the manufacturing of drug substances and drug products for all of its products in clinical development. As of December 31, 2013 the Company owned approximately 25 U.S. patents and patent applications. It competes with pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations which are developing various approaches to cancer therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its product candidates.

Top Ranked Articles about Cascadian Therapeutics Inc

Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Klarman takes 18 percent of cancer treatment developer as FDA fast-tracks product
Seth Klarman (Trades, Portfolio) continues to top weight his portfolio with outsized stakes in health care and pharmaceutical companies. June 30, he bought 18.5% of a company designing a treatment for breast cancer. Read more...
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Company has zero debt and is trading close to a 5-year low
Seth Klarman (Trades, Portfolio) purchased 25 million shares in biotechnology company Cascadian Therapeutics Inc. (NASDAQ:CASC) on June 30. Klarman paid 94 cents per share in a deal that had a 0.34% impact on his portfolio. Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.24
CASC's PB Ratio is ranked higher than
88% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. CASC: 1.24 )
Ranked among companies with meaningful PB Ratio only.
CASC' s PB Ratio Range Over the Past 10 Years
Min: 0.74  Med: 3.86 Max: 23.62
Current: 1.24
0.74
23.62
Current Ratio 7.35
CASC's Current Ratio is ranked higher than
71% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CASC: 7.35 )
Ranked among companies with meaningful Current Ratio only.
CASC' s Current Ratio Range Over the Past 10 Years
Min: 2.8  Med: 10.64 Max: 26.84
Current: 7.35
2.8
26.84
Quick Ratio 7.35
CASC's Quick Ratio is ranked higher than
72% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CASC: 7.35 )
Ranked among companies with meaningful Quick Ratio only.
CASC' s Quick Ratio Range Over the Past 10 Years
Min: 2.37  Med: 10.64 Max: 26.84
Current: 7.35
2.37
26.84

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 2.31
CASC's 5-Year Yield-on-Cost % is ranked higher than
64% of the 268 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. CASC: 2.31 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CASC' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.1
Current: 2.31
0
3.1
3-Year Average Share Buyback Ratio -24.20
CASC's 3-Year Average Share Buyback Ratio is ranked lower than
73% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CASC: -24.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CASC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -33  Med: -14.6 Max: -3.9
Current: -24.2
-33
-3.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.72
CASC's Price-to-Net-Cash is ranked higher than
89% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. CASC: 1.72 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CASC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.04  Med: 4.84 Max: 12.85
Current: 1.72
1.04
12.85
Price-to-Net-Current-Asset-Value 1.67
CASC's Price-to-Net-Current-Asset-Value is ranked higher than
90% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. CASC: 1.67 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CASC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.91  Med: 4.89 Max: 12.39
Current: 1.67
0.91
12.39
Price-to-Tangible-Book 1.61
CASC's Price-to-Tangible-Book is ranked higher than
86% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. CASC: 1.61 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CASC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84  Med: 4.43 Max: 10.56
Current: 1.61
0.84
10.56
Earnings Yield (Greenblatt) % -46.29
CASC's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. CASC: -46.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CASC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -48.16  Med: 154.1 Max: 6690.6
Current: -46.29
-48.16
6690.6

More Statistics

EPS (TTM) $ -3.31
Beta3.12
Short Percentage of Float7.24%
52-Week Range $3.49 - 10.98
Shares Outstanding (Mil)22.56

Analyst Estimate

Dec18
Revenue (Mil $)
EPS ($) -0.43
EPS without NRI ($) -0.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CASC

Headlines

Articles On GuruFocus.com
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Jul 11 2016 
Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
Cubist Pharmaceutical - Acutely Aware May 09 2010 

More From Other Websites
CASCADIAN THERAPEUTICS, INC. Financials Mar 15 2017
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Mar 13 2017
Cascadian Therapeutics Announces Changes to Board of Directors Mar 13 2017
Cascadian Therapeutics reports 4Q loss Mar 09 2017
Cascadian Therapeutics reports 4Q loss Mar 09 2017
CASCADIAN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Mar 09 2017
Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results Mar 09 2017
Cascadian Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference Feb 27 2017
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement Feb 03 2017
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jan 27 2017
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 24 2017
Cascadian Therapeutics Prices $82.5 Million Concurrent Offerings of Common Stock and Preferred Stock Jan 24 2017
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jan 23 2017
Cascadian Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred... Jan 23 2017
Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress Jan 05 2017
Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress Jan 05 2017
Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President, Regulatory Affairs and... Jan 04 2017
Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President, Regulatory Affairs and... Jan 04 2017
Should You Buy Alico, Inc. (ALCO)? Dec 20 2016
Here’s What Smart Money Think about Jones Energy Inc (JONE) Dec 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)